Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2019 | DXA01 | Platform/Oral | Disease Assessment and Management |
Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment |
Michelle H Cameron, MD, PT, MCR1, Jeffrey A Cohen, MD2, Aaron E Miller, MD3, Andrew Goodman, MD4, Myla D Goldman, MD, Msc5, Dustin Chernick, PhD6, Robert Elfont, M.D.6, Cindy Souza-Prien, B.S.6, Larissa Felt, B.S.6 and Rajiv Patni, MD6, (1)Oregon Health & Science University, Portland, OR, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)Icahn School of Medicine at Mount Sinai, New York, NY, (4)Neurology, University of Rochester, Rochester, NY, (5)University of Virginia, Charlottesville, VA, (6)Adamas Pharmaceuticals, Inc., Emeryville, CA |
| 2019 | DXA02 | Platform/Oral | Disease Assessment and Management |
Sleep Quality and Physical Activity in Youth with Multiple Sclerosis |
Stephanie A Grover, MSc, CCRP1, Samantha Stephens, PhD1, Kimberly Young, BHSc, MSc1, Tara Berenbaum, BSc1, Renisha Iruthayanathan, BSc1, Austin Noguera, BA1, Michelle J Jaeggi, MD2, Marcia Finlayson, PhD, OT Reg (Ont), OTR3, Robert W Motl, PhD4, Shelly Weiss, MD, FRCPC2,5, Indra Narang, MEDSCI, MBBCH, FRCPCH, MD6 and E Ann Yeh, MD2,5,7, (1)Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada, (2)Division of Neurology, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada, (3)School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada, (4)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (5)Faculty of Medicine, University of Toronto, Toronto, ON, Canada, (6)Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada, (7)Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada |
| 2019 | DXA03 | Platform/Oral | Disease Assessment and Management |
Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? |
Giulia Longoni, M.D.1, Beyza Ciftci-Kavaklioglu, MD1, Carmen Yea, MSc2, Stephanie A Grover, MSc, CCRP2, Fahad Albassam, MD1, Renisha Iruthayanathan, BSc2 and E Ann Yeh, MD1, (1)Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada, (2)Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada |
| 2019 | DXA04 | Platform/Oral | Disease Assessment and Management |
Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis |
Stacy Coffyn, SPT1, Alexandra Wileman, SPT1, Samantha D’Silva, SPT1, Mohammed Alshehri, PT, MS1, Michelle Drerup, Psy.D., D.BSM2, Sharon G Lynch, MD3 and Catherine Siengsukon, PT, PhD1, (1)Physical Therapy and Rehabilitation Science, University of Kansas Medical Center, Kansas City, KS, (2)Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, (3)Neurology, University of Kansas Medical Center, Kansas City, KS |
| 2019 | DXA05 | Platform/Oral | Disease Assessment and Management |
Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan. |
Katie LJ Cederberg, MS1, Jessica F Baird, PhD1, Stephanie L Silveira, PhD1, Brenda Jeng, MS1, E. Morghen Sikes, MS, OTR/L1 and Robert W Motl, PhD2, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL |
| 2019 | DXA06 | Platform/Oral | Disease Assessment and Management |
The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) |
Terrie Livingston, PharmD1, Yang Mao-Draayer, MD, PhD2, Kottil Rammohan, MD3, David Li, MD, FRCPC4, June Halper, MSN, ANP, FAAN5, Sara McCurdy Murphy, BA6 and Lisa Patton, BA6, (1)EMD Serono, Rockland, MA, (2)Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, (3)University of Miami, Miami, FL, (4)The University of British Columbia, Vancouver, BC, Canada, (5)CEO-CMSC, Hackensack, NJ, (6)CRB, Social & Scientific Systems, Inc., Silver Spring, MD |
| 2019 | DXM01 | Platform/Oral | Disease Management, Imaging and Therapeutics |
Efficacy and Safety of Alemtuzumab in Patients of African Descent in Care-MS I and II: 8-Year Follow-up (TOPAZ Study) |
Annette Okai, MD1, Lilyana Amezcua, MD, MS2, Regina Berkovich, MD2,3, Angel Chinea, MD4, Keith Edwards, MD5, Brian Steingo, MD6, Aljoeson Walker, MD7, Alan Jacobs, MD8, Nadia Daizadeh, PhD8, Mitzi Williams, MD9 and on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators, (1)Multiple Sclerosis Treatment Center of Dallas, Dallas, TX, (2)Keck School of Medicine, University of Southern California, Los Angeles, CA, (3)Synergy Healthcare Medical Associates, Los Angeles, CA, (4)San Juan Multiple Sclerosis Center, Guaynabo, PR, (5)MS Center of Northeastern New York, Latham, NY, (6)Fort Lauderdale Multiple Sclerosis Center, Fort Lauderdale, FL, (7)Medical University of South Carolina, Charleston, SC, (8)Sanofi, Cambridge, MA, (9)Multiple Sclerosis Center of Atlanta, Mableton, GA |
| 2019 | DXM02 | Platform/Oral | Disease Management, Imaging and Therapeutics |
Treatment Patterns of Disease-Modifying Therapy Among Pediatric Patients with Multiple Sclerosis in the United States |
Benjamin Greenberg, MD, MHS1, Scott Kolodny, MD2, Mengru Wang, MS3 and Chinmay Deshpande, PhD2, (1)Department of Neurology, UT Southwestern, Dallas, TX, (2)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (3)KMK Consulting Inc, Morristown, NJ |
| 2019 | DXM03 | Platform/Oral | Disease Management, Imaging and Therapeutics |
Changes in the Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis: Interim Results of the FLUENT Study |
Yang Mao-Draayer, MD, PhD1, Jeffrey A Cohen, MD2, Amit Bar-Or, MD3, Bruce A C Cree, MD, PhD, MAS4, May H Han, MD5, Barry A Singer, MD6, Scott Kolodny, MD7, Xiangyi Meng, PhD7, Lesley Schofield, PhD7 and Marina Ziehn, PhD7, (1)University of Michigan, Ann Arbor, MI, (2)Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH, (3)Center for Neuroinflammation and Experimental Therapeutics, and Multiple Sclerosis Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, (4)Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, (5)Stanford University, Stanford, CA, (6)Missouri Baptist Medical Center, St. Louis, MO, (7)Novartis Pharmaceuticals Corporation, East Hanover, NJ |
| 2019 | DXM04 | Platform/Oral | Disease Management, Imaging and Therapeutics |
Real-World Efficacy of Delayed-Release Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 24-Month Interim Results from Esteem |
Mitzi Williams, MD1, Lilyana Amezcua, MD, MS2, Stephen Krieger, MD3, Annette Okai, MD4, Darin T Okuda, MD5, Ray Su, PhD6, Sami Fam, PhD6, James B. Lewin, PharmD6 and Cynthia C Jones, PhD6, (1)Multiple Sclerosis Center of Atlanta, Mableton, GA, (2)Keck School of Medicine, University of Southern California, Los Angeles, CA, (3)Icahn School of Medicine at Mount Sinai, New York City, NY, (4)Multiple Sclerosis Treatment Center Of Dallas at Baylor University Medical Center, Dallas, TX, (5)UT Southwestern Medical Center, Dallas, TX, (6)Biogen, Cambridge, MA |
| 2019 | DXM05 | Platform/Oral | Disease Management, Imaging and Therapeutics |
The Effects of Cladribine Tablets on Reduction in MRI Lesions Are Consistent across Subgroups in the Oracle-MS Study |
Thomas Leist, MD1, Doris Damian, PhD2, Yann Hyvert, PhD3, Fernando Dangond, MD4, Daniel Jones, PhD3 and Bruce Hughes, MD5, (1)Thomas Jefferson University, Philadelphia, PA, (2)EMD Serono, Inc., Billerica, MA, (3)EMD Serono, Inc., Rockland, MA, (4)Global Clinical Development Center, EMD Serono, Inc., Billerica, MA, (5)Mercy Ruan Multiple Sclerosis Center, Des Moines, IA |
| 2019 | DXM06 | Platform/Oral | Disease Management, Imaging and Therapeutics |
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing MS over 48 Weeks: A Phase II Study |
| 2019 | PSY01 | Platform/Oral | Psychosocial: Cognition, Depression |
Cognition Following Mesenchymal Stem Cell Therapy in Multiple Sclerosis: An Interim Analysis |
Maha Abu-AlHawa, M.A.1, Mark S Freedman, MSc, MD, FAAN, FRCPC2, Harold Atkins, MD3 and Lisa A.S. Walker, PhD1,4,5, (1)Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada, (2)THe University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada, (3)Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada, (4)Psychology, Carleton University, Ottawa, ON, Canada, (5)Psychology, University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada |
| 2019 | PSY02 | Platform/Oral | Psychosocial: Cognition, Depression |
Contributions of the Rey Auditory Verbal Learning Test to Cognitive Impairment on the Brief International Cognitive Assessment for Multiple Sclerosis |
Abbey J Hughes, PhD1, Aeysha Brown, MA1,2, Krina Patel, BS1,2 and Meghan Beier, PhD1, (1)Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, (2)American School of Professional Psychology at Argosy University – Northern Virginia, Arlington, VA |
| 2019 | PSY03 | Platform/Oral | Psychosocial: Cognition, Depression |
Neurobehavioral Correlates of Hazardous Cannabis Use in Multiple Sclerosis |
Abbey J Hughes, PhD1, Aeysha Brown, MA1,2, Krina Patel, BS1,2, Trisha Chaffee, MS1 and Meghan Beier, PhD1, (1)Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD, (2)American School of Professional Psychology at Argosy University – Northern Virginia, Arlington, VA |
| 2019 | PSY04 | Platform/Oral | Psychosocial: Cognition, Depression |
Using Connectome-Based Predictive Modeling to Derive Neuromarkers of Cognition in MS |
Ruchika S. Prakash, Ph.D., Heena R. Manglani, M.A., Stephanie Fountain-Zaragoza, M.A., Anita Shankar, M.A. and Daniel Evans, B.A., Department of Psychology, The Ohio State University, Columbus, OH |
| 2019 | PSY05 | Platform/Oral | Psychosocial: Cognition, Depression |
Correlates of Cognitive Performance and Perceived Cognitive Abilities Among Hispanic and Black Individuals with Multiple Sclerosis |
Alexa Stuifbergen, RN, PhD, FAAN, Heather Becker, PhD, Research Scientist and Wenhui Zhang, BSN; PhD Candidate, School of Nursing, The University of Texas at Austin, Austin, TX |
| 2019 | PSY06 | Platform/Oral | Psychosocial: Cognition, Depression |
How Anxiety and Fatigue Interact to Interfere with Processing Speed in MS |
Caroline Altaras, MA1, Jennifer Miller, MA2, Nicholas Vissichio, MA2 and Fred Foley, PhD2,3, (1)Ferkauf Graduate School of Psychology, Yeshiva University, Bronx, NY, (2)Ferkauf Graduate School of Psychology, Yeshiva University, New York, NY, (3)Holy Name Medical Center, Teaneck, NJ |
| 2019 | RHI01 | Platform/Oral | Rehabilitation Interventions |
Environmental Correlates of Physical Activity in Persons with Multiple Sclerosis |
Stephanie L Silveira, PhD, Physical Therapy, University of Alabama at Birmingham, Birmingham, AL and Robert W Motl, PhD, Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL |
| 2019 | RHI02 | Platform/Oral | Rehabilitation Interventions |
Physical Activity and Walking Performance across the Lifespan in Multiple Sclerosis |
| 2019 | RHI03 | Platform/Oral | Rehabilitation Interventions |
Physical and Cognitive Fatigue across the Lifespan in Persons with Multiple Sclerosis |
Catherine D Jones, MSPH1, Katie LJ Cederberg, MS1, E. Morghen Sikes, MS, OTR/L1, Robert W Motl, PhD2 and Brian M Sandroff, PhD1, (1)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (2)Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL |
| 2019 | RHI04 | Platform/Oral | Rehabilitation Interventions |
Psychometric Comparisons of Computer-Adaptive Test and Standard Balance and Walking Scales to Assess Functional Mobility in People with MS |
Hina Garg, PT, MS, PhD, NCS and Andre Scholes, SPT, Physical Therapy, Rocky Mountain University of Health Professions, Provo, UT |
| 2019 | RHI05 | Platform/Oral | Rehabilitation Interventions |
Persons with Multiple Sclerosis with Severe Disability Exhibit Muscular Strength Asymmetries in Both Upper and Lower Extremities |
John W Farrell III, PhD1, Rob Motl, PhD2, Yvonne C Learmonth, PhD3 and Lara A. Pilutti, PhD1, (1)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (2)Physical Therapy, University of Alabama at Birmingham, Birmingham, AL, (3)School of Psychology and Exercise Science, Murdoch University, Perth, Australia |
| 2019 | RHI06 | Platform/Oral | Rehabilitation Interventions |
Manual Dexterity and Computerized Cognitive Testing in People with Multiple Sclerosis: Motor Domain Reflects More Than Just What Is in the Hand |
Daniel Golan, MD1, Jeffrey Wilken, PhD2, Nicholas Jawrower, N/A3, Jared Srinivasan, BA3, Annina Giannuzzi, BS3, Cynthia Sullivan, PhD4, Barbara Bumstead, MS, ANCP, MSCN3, Marijean Buhse, PhD, NP, RN, MSCN3 and Mark Gudesblatt, MD3, (1)Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, (2)Washington Neuropsychology Research Group, Washington, DC, (3)South Shore Neurologic Associates, Patchogue, NY, (4)Nursing, State University of New York @ Stony Brook, Stony Brook, NY |
| 2019 | CAM01 | Poster | Complementary and Alternative Therapies |
Methods to Improve Vitamin D Supplementation Compliance in Patients with Multiple Sclerosis |
Claire Hara-Cleaver, CNP, The Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH and Malissa C Ayers, Physician Assistant, Mellen Center, Cleveland Clinic Foundation, Cleveland, OH |
| 2019 | CAM02 | Poster | Complementary and Alternative Therapies |
Comparing Gastrointestinal Tolerability and Absorption of Racemic and R-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Cross-over Trial |
Cassidy A Taylor, BA1, Michelle H Cameron, MD, PT, MCR1,2, Jodi Lapidus, PhD1,3, Naghmeh Daneshi, ABD3 and Rebecca I Spain, MD, MSPH1,2, (1)Oregon Health & Science University, Portland, OR, (2)VA Portland Health Care System, Portland, OR, (3)Oregon Health & Science University – Portland State University School of Public Health, Portland, OR |
| 2019 | CAM03 | Poster | Complementary and Alternative Therapies |
The Effects of Acupuncture on Mobility and Sensorimotor Function, in Persons with Multiple Sclerosis. Partial Results of an Ongoing Study |
Barbara Siminovich-Blok, ND, LAc, MS, NYU Langone Medical Center, New York, NY, Herb Karpatkin, PT, DSc, NCS, MSCS, Physical Therapy, Hunter College, New York, NY, Zabrina Langer, PT, DPT, NCS, Physical therapy, NYU Langone, New York, NY, Dana Lotan, PT, DPT, NCS, GCS, Physical therapy, Rusk Rehabilitation, New York, NY, Sophia Maguire, BSc, MA, NYU Langone medicaenterNew york, New york, NY and Stephanie Winsor, BA, NYU Langone Medcial Center, New York, NY |
| 2019 | CAM04 | Poster | Complementary and Alternative Therapies |
Understanding the Impact of Disability on Dietary Intake and Patterns in People with Multiple Sclerosis |
Myriam Venasse, BSc1, Amanda Gauthier, MSc, RD2, Isabelle Giroux, PhD, RD3 and Lara A. Pilutti, PhD1, (1)Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada, (2)Clinical Nutrition Department, Niagara Health System, Niagara Falls, ON, Canada, (3)School of Nutrition Sciences, University of Ottawa, Ottawa, ON, Canada |
| 2019 | CAM05 | Poster | Complementary and Alternative Therapies |
Nutritional Composition of Diet of Individuals with Multiple Sclerosis Following a Modified Paleolithic Diet |
Babita Bisht, PT, PhD1, Linda G. Snetselaar, PhD2, Catherine A. Chenard, MS, RDN1 and Terry L. Wahls, MD1, (1)Department of Internal Medicine, University of Iowa, Iowa City, IA, (2)Department of Epidemiology, University of Iowa, Iowa City, IA |
| 2019 | CSR01 | Poster | Case Reports/Case Series |
A Hip Flexion Assist Orthosis Improves Walking in Advanced Multiple Sclerosis: A Retrospective Case Report |
Matthew G Spilsbury, DPT, Physical Therapy, Encompass Health Rehabiliation Hospital, Colorado Springs, CO |
| 2019 | CSR02 | Poster | Case Reports/Case Series |
Fulminant and Aggressive Multiple Sclerosis after Fingolimod Cessation |
Susan E Agland, Master Research with Training (Nursing), RN, MS Clinic, Neurology, Hunter New England Local Health District, Newcastle, Australia and Jeannette Lechner-Scott, FRACP, John Hunter Hospital, Newcastle, Australia |
| 2019 | CSR03 | Poster | Case Reports/Case Series |
Cadasil with Positive CSF Oligoclonal Bands Initially Misdiagnosed As Multiple Sclerosis |
William A Kilgo, MD, Neurology, University of South Alabama, Mobile, AL |
| 2019 | CSR04 | Poster | Case Reports/Case Series |
Fingolimod-Induced Immune Thrombocytopenic Purpura (ITP) |
Loulwah Mukharesh, MD, Neurology, The George Washington University Hospital, Washington, DC and Ted L Rothstein, MD, Neurology, George Washington University, Washington, DC |
| 2019 | CSR05 | Poster | Case Reports/Case Series |
Infliximab-Induced Optic Neuritis and Facial Myositis |
Loulwah Mukharesh, MD and Amanda Tinsley, MD, Neurology, The George Washington University Hospital, Washington, DC |
| 2019 | CSR06 | Poster | Case Reports/Case Series |
Minimally Invasive Trigeminal Ablation (MITA) in Multiple Sclerosis Patients with Medically Refractory Trigeminal Neuralgia (a case series) |
Yasser Tajali, M.D.1, Max Ward, B.S.2, Yehuda Herschman, M.D.2, Boris Paskhover, M.D.3 and Machteld E Hillen, MD1, (1)Neurology, Rutgers New Jersey Medical School, Newark, NJ, (2)Neurosurgery, Rutgers New Jersey Medical School, Newark, NJ, (3)Otolaryngology, Rutgers New Jersey Medical School, Newark, NJ |
| 2019 | CSR07 | Poster | Case Reports/Case Series |
An Interesting Case of Acute Liver Injury from High Dose Pulse Steroid Therapy in a Patient with Multiple Sclerosis (MS). |
Aiga Rakhesh, MD1,2, Poonam Ochani, MD3, Lori Hoffman, NP3 and Steven Brose, DO3, (1)SCI Neurology, Syracuse VA Medical Center, Syracuse, NY, (2)Neurology, Suny Upstate Medical Univeristy, Syracuse, NY, (3)SCI, Syracuse VA Medical Center, Syracuse, NY |
| 2019 | CSR08 | Poster | Case Reports/Case Series |
SSA Positivity a Predictor of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder |
Roberto A Cruz, MD1, Alexander B Ramos, MD1, Miguel F Molina, MD, PhD1, Bridget A Bagert, MD2 and Jesus F Lovera, MD1, (1)Neurology, Louisiana University Health Science Center, New Orleans, LA, (2)Neurology, Ochsner Clinic Foundation, New Orleans, LA |
| 2019 | CSR09 | Poster | Case Reports/Case Series |
Clippers Achieved Clinical and Radiological Stability Using Rituximab: Report of One Case |
Roberto A Cruz, MD1, Christopher M Smith, MD1, Mary M Nguyen, MD2 and Jesus F Lovera, MD1, (1)Neurology, Louisiana University Health Science Center, New Orleans, LA, (2)Neurology, Louisiana University health Science Center, New Orleans, LA |
| 2019 | CSR10 | Poster | Case Reports/Case Series |
Physical Therapist Differential Diagnosis for an Individual with Multiple Sclerosis. |
Annessa L Nixon, PT, DPT, MSCS, Nashville, TN |
| 2019 | CSR11 | Poster | Case Reports/Case Series |
Psoriasis Flare during Ocrelizumab Therapy for Relapsing Multiple Sclerosis: Report of 2 Cases |
Hannah M Geils, B.S., Joshua D Katz, M.D., Ellen S Lathi, MD and India C Stribling, B.S., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |